Esperion Therapeutics Company Profile (NASDAQ:ESPR)

About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics logoEsperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ESPR
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.27618 billion
  • Outstanding Shares: 22,593,000
Average Prices:
  • 50 Day Moving Avg: $48.34
  • 200 Day Moving Avg: $40.88
  • 52 Week Range: $9.40 - $57.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.28
  • P/E Growth: -1.20
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.82 per share
  • Price / Book: 7.28
  • EBIDTA: ($131,290,000.00)
  • Return on Equity: -62.82%
  • Return on Assets: -57.32%
  • Current Ratio: 5.52%
  • Quick Ratio: 5.52%
  • Average Volume: 761,517 shs.
  • Beta: 2.69
  • Short Ratio: 10.97

Frequently Asked Questions for Esperion Therapeutics (NASDAQ:ESPR)

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($1.67) by $0.25. During the same period last year, the company earned ($0.62) EPS. View Esperion Therapeutics' Earnings History.

Where is Esperion Therapeutics' stock going? Where will Esperion Therapeutics' stock price be in 2017?

13 equities research analysts have issued 12-month price targets for Esperion Therapeutics' stock. Their predictions range from $12.50 to $85.00. On average, they expect Esperion Therapeutics' stock price to reach $55.21 in the next twelve months. View Analyst Ratings for Esperion Therapeutics.

What are analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:

  • 1. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (8/23/2017)
  • 2. Needham & Company LLC analysts commented, "The FDA has agreed that the Phase III CLEAR LDL program of bempedoic acid is sufficient to support approval. This resolves a long standing issue for ESPR shares regarding the ability to get their drug approved without a completed CVOT. This regulatory confirmation comes on the heals of the positive FOURIER outcomes data for Repatha and the genetic validation of the target for bempedoic acid which was presented yesterday at the American College for Cardiology (ACC). As a result of this trifecta of positive news we are increasing our price target on ESPR to $58 from $25. We once again model US approval based on CLEAR LDL in 2020." (3/20/2017)

Who are some of Esperion Therapeutics' key competitors?

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the folowing people:

  • Timothy M. Mayleben, President, Chief Executive Officer, Director
  • Narendra D. Lalwani Ph.D., FAHA, DABT, Chief Operating Officer, Executive Vice President - Research & Development
  • Mary P. McGowan M.D., Chief Medical Officer
  • Nicole Vitullo MBA, Independent Lead Director
  • Roger S. Newton Ph.D., FAHA, FACN, Director
  • Scott N. Braunstein M.D., Independent Director
  • Dov A. Goldstein M.D., Independent Director
  • Antonio M. Gotto Jr., M.D., Ph.D., Independent Director

Who owns Esperion Therapeutics stock?

Esperion Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include MEDITOR GROUP LTD (8.20%), BB Biotech AG (6.70%), State Street Corp (6.67%), FMR LLC (5.93%), Discovery Capital Management LLC CT (4.27%) and Vanguard Group Inc. (3.35%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.

Who sold Esperion Therapeutics stock? Who is selling Esperion Therapeutics stock?

Esperion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Northern Trust Corp, Quantitative Investment Management LLC, Pinnacle Associates Ltd., Virtu KCG Holdings LLC, EAM Investors LLC, GSA Capital Partners LLP and Paulson & CO. Inc.. View Insider Buying and Selling for Esperion Therapeutics.

Who bought Esperion Therapeutics stock? Who is buying Esperion Therapeutics stock?

Esperion Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Discovery Capital Management LLC CT, Meditor Group Ltd, Peregrine Capital Management LLC, Pictet Asset Management Ltd., Lord Abbett & CO. LLC, Teachers Advisors LLC and BB Biotech AG. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.

How do I buy Esperion Therapeutics stock?

Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of Esperion Therapeutics stock can currently be purchased for approximately $49.67.

MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  252 (Vote Underperform)
Total Votes:  537
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.62)
Consensus Price Target: $55.21 (11.15% upside)

Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/7/2017Cowen and CompanyInitiated CoverageOutperform$64.00LowView Rating Details
8/29/2017Northland SecuritiesInitiated CoverageOutperform -> Outperform$72.00MediumView Rating Details
8/21/2017Jefferies Group LLCReiterated RatingBuy$85.00LowView Rating Details
8/11/2017Bank of America CorporationReiterated RatingNeutral -> Neutral$60.00MediumView Rating Details
8/10/2017Stifel NicolausReiterated RatingBuy$60.00 -> $70.00HighView Rating Details
8/9/2017Deutsche Bank AGSet Price TargetBuy$48.00 -> $64.00HighView Rating Details
8/8/2017Needham & Company LLCBoost Price TargetBuy -> Positive$58.00 -> $72.00HighView Rating Details
6/22/2017Citigroup Inc.Reiterated RatingBuyHighView Rating Details
3/20/2017J P Morgan Chase & CoReiterated RatingHold$22.00 -> $50.00MediumView Rating Details
3/20/2017Royal Bank Of CanadaReiterated RatingHold$45.00HighView Rating Details
3/20/2017Credit Suisse GroupUpgradeUnderperform -> Neutral$29.00HighView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/15/2016Chardan CapitalReiterated RatingNeutral$12.50N/AView Rating Details
8/31/2016Barclays PLCSet Price TargetHold$13.00N/AView Rating Details
7/5/2016WallachBeth CapitalDowngradeBuy -> Hold$35.00N/AView Rating Details
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 -> $27.00N/AView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for Esperion Therapeutics (NASDAQ:ESPR)
Earnings by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Earnings History by Quarter for Esperion Therapeutics (NASDAQ ESPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($1.67)($1.92)ViewListenView Earnings Details
5/1/2017Q1 2017($1.44)($1.80)ViewN/AView Earnings Details
2/22/201712/31/2016($1.24)($1.29)ViewN/AView Earnings Details
11/3/2016Q3($0.82)($0.77)ViewN/AView Earnings Details
8/4/2016Q2($0.78)($0.62)ViewN/AView Earnings Details
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details
2/25/2016Q4($0.61)($0.58)ViewN/AView Earnings Details
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details
5/7/2015Q115($0.54)($0.56)ViewN/AView Earnings Details
3/5/2015Q4 2014($0.54)($0.49)ViewN/AView Earnings Details
8/12/2014Q214($0.55)($0.60)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.62)($0.51)ViewN/AView Earnings Details
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($1.38)($1.38)($1.38)
Q3 20171($1.78)($1.78)($1.78)
Q4 20171($1.95)($1.95)($1.95)
(Data provided by Zacks Investment Research)


Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Esperion Therapeutics (NASDAQ:ESPR)
Insider Ownership Percentage: 32.50%
Institutional Ownership Percentage: 83.30%
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/22/2017Dov A Md GoldsteinDirectorSell800,000$41.66$33,328,000.00View SEC Filing  
3/21/2017Gilbert S OmennDirectorBuy1,000$42.26$42,260.00View SEC Filing  
11/1/2016Narendra D LalwaniCOOBuy5,000$9.93$49,650.00View SEC Filing  
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00View SEC Filing  
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.00View SEC Filing  
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.00View SEC Filing  
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.00View SEC Filing  
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.00View SEC Filing  
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Esperion Therapeutics (NASDAQ:ESPR)
Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
DateHeadline logoReviewing Esperion Therapeutics (ESPR) & Its Competitors - September 17 at 12:32 AM logo Brokerages Expect Esperion Therapeutics, Inc. (ESPR) to Post -$1.78 Earnings Per Share - September 14 at 4:14 PM logoHead-To-Head Survey: Esperion Therapeutics (ESPR) vs. Its Competitors - September 14 at 8:20 AM logoCowen and Company Initiates Coverage on Esperion Therapeutics, Inc. (ESPR) - September 10 at 9:54 AM logoHead to Head Contrast: ICON PLC (ICLR) & Esperion Therapeutics (ESPR) - September 2 at 6:08 AM logoEsperion Therapeutics, Inc. (ESPR) Given Average Recommendation of "Buy" by Analysts - August 30 at 4:44 PM logoEsperion Therapeutics, Inc. (ESPR) Now Covered by Northland Securities - August 29 at 10:16 AM logoCramer Remix: Here's how North Korea's missile could impact the stock market - August 29 at 4:15 AM logoEsperion Therapeutics, Inc. (ESPR) Upgraded by Zacks Investment Research to Hold - August 23 at 5:58 PM logoEsperion Therapeutics, Inc. (ESPR) to Post Q3 2017 Earnings of ($1.78) Per Share, Jefferies Group Forecasts - August 23 at 8:22 AM logoEsperion Therapeutics, Inc. (ESPR) Stock Rating Reaffirmed by Jefferies Group LLC - August 21 at 11:10 AM logoEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives "Neutral" Rating from Bank of America Corporation - August 13 at 1:38 PM logoEsperion Announces Inducement Grants Under NASDAQ Listing ... - Nasdaq - August 12 at 4:55 AM logoJefferies Group Weighs in on Esperion Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:ESPR) - August 11 at 9:34 AM logoEsperion Therapeutics, Inc. (ESPR) Downgraded to Sell at Zacks Investment Research - August 10 at 7:46 PM logoEsperion Therapeutics (ESPR) Prices 3.1M Share Common Offering at $49/Sh - August 10 at 7:43 PM logoEsperion Prices Public Offering of Common Stock - August 9 at 11:39 PM logoBenzinga's Top Upgrades, Downgrades For August 9, 2017 - Benzinga - August 9 at 6:37 PM logoPositive Triplet Data Should Accelerate Esperion Deal-Making Chatter - Seeking Alpha - August 9 at 6:37 PM logoEdited Transcript of ESPR earnings conference call or presentation 8-Aug-17 12:30pm GMT - August 9 at 4:10 AM logoEsperion Therapeutics' (ESPR) CEO Tim Mayleben on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 8 at 11:10 PM logoEsperion Therapeutics, Inc. (ESPR) Expected to Announce Earnings of -$1.67 Per Share - August 8 at 6:24 PM logoEsperion Therapeutics (ESPR) Says Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin Met ... - - August 8 at 6:09 PM logoInvestor Network: Esperion Therapeutics, Inc. to Host Earnings Call - August 8 at 6:09 PM logoEsperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin - August 8 at 6:09 PM logoEsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results - August 8 at 6:09 PM logoHere's What's Pushing Up Esperion Therapeutics Inc. Today - August 8 at 6:09 PM logoEsperion Announces Proposed Public Offering of Common Stock - August 8 at 6:08 PM logoEsperion Therapeutics reports 2Q loss - August 8 at 6:08 PM logoEsperion Therapeutics, Inc. (ESPR) Upgraded by Jefferies Group LLC to Buy - August 8 at 5:42 PM logoEsperion Therapeutics, Inc. (ESPR) Releases Quarterly Earnings Results, Misses Estimates By $0.30 EPS - August 8 at 3:48 PM logoNeedham & Company LLC Increases Esperion Therapeutics, Inc. (NASDAQ:ESPR) Price Target to $72.00 - August 8 at 1:20 PM logoShould You Buy Esperion Therapeutics (ESPR) Ahead of Earnings? - August 7 at 6:41 PM logoBidaskClub Downgrades Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Buy - August 6 at 11:20 AM logoEsperion Therapeutics Inc (NASDAQ:ESPR) Receives Consensus Recommendation of "Buy" from Brokerages - August 5 at 4:40 PM logoEsperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results - August 2 at 7:20 PM logoJuno Therapeutics (JUNO) Q2 Earnings: Surprise in Store? - July 27 at 11:59 PM logoEsperion Therapeutics (ESPR) Reports Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor - July 27 at 11:59 PM logoThe CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug - Motley Fool - July 26 at 6:59 PM logoEsperion Therapeutics (ESPR) Reports Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor - - July 26 at 6:59 PM logoEsperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor - July 26 at 6:59 PM logo3 Small Biotech Stocks Being Run by Proven Winners - July 17 at 10:56 AM logoEsperion Therapeutics, Inc. (ESPR) to Post Q2 2017 Earnings of ($1.38) Per Share, Jefferies Group Forecasts - July 13 at 10:02 AM logoEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of "Buy" from Brokerages - July 11 at 5:34 PM logoEsperion Therapeutics, Inc. (ESPR) Coverage Initiated by Analysts at Jefferies Group LLC - July 10 at 5:26 PM logo3 Stocks That Turned $7,000 Into As Much As $37,000 So Far in 2017 - July 8 at 10:33 AM logoEsperion Therapeutics: Is Investor Enthusiasm Justified? - Seeking Alpha - July 6 at 1:50 AM logoBiotech Movers: Akebia Shares Down After Pricing Stock Offering - - June 30 at 6:01 AM logoToday's Research Reports on Stocks to Watch: Heat Biologics Inc. and Esperion Therapeutics - June 29 at 7:56 PM logoHere's Why Shares of Esperion Therapeutics (ESPR) Popped Today - Nasdaq - June 29 at 4:51 AM



Esperion Therapeutics (ESPR) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff